Your browser doesn't support javascript.
loading
The Risk of Sympathetic Ophthalmia Associated with Open-Globe Injury Management Strategies: A Meta-analysis.
Patterson, Tim J; Kedzierski, Adam; McKinney, David; Ritson, Jonathan; McLean, Chris; Gu, Weidong; Colyer, Marcus; McClellan, Scott F; Miller, Sarah C; Justin, Grant A; Hoskin, Annette K; Cavuoto, Kara; Leong, James; Rousselot Ascarza, Andrés; Woreta, Fasika A; Miller, Kyle E; Caldwell, Matthew C; Gensheimer, William G; Williamson, Tom; Dhawahir-Scala, Felipe; Shah, Peter; Coombes, Andrew; Sundar, Gangadhara; Mazzoli, Robert A; Woodcock, Malcolm; Watson, Stephanie L; Kuhn, Ferenc; Halliday, Sophia; Gomes, Renata S M; Agrawal, Rupesh; Blanch, Richard J.
Afiliación
  • Patterson TJ; Northern Ireland Medical and Dental Training Agency (NIMDTA), Beflast, United Kingdom.
  • Kedzierski A; Frimley Health NHS Trust, Frimley, United Kingdom.
  • McKinney D; Northern Ireland Medical and Dental Training Agency (NIMDTA), Beflast, United Kingdom.
  • Ritson J; Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom; Royal Centre for Defence Medicine, Birmingham, United Kingdom.
  • McLean C; Epsom and St Helier University Hospitals NHS Trust, Epsom, United Kingdom.
  • Gu W; Vision Center of Excellence, Research & Development Directorate, J-9, Defence Health Agency, Silver Spring, Maryland.
  • Colyer M; Uniformed Services University of the Health Sciences, Bethesda, Maryland.
  • McClellan SF; Vision Center of Excellence, Research & Development Directorate, J-9, Defence Health Agency, Silver Spring, Maryland.
  • Miller SC; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Justin GA; Uniformed Services University of the Health Sciences, Bethesda, Maryland; Duke Eye Center, Duke University Hospitals, Durham, North Carolina.
  • Hoskin AK; The University of Sydney, Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, Sydney, New South Wales, Australia; Lions Eye Institute, University of Western Australia, Perth, Australia.
  • Cavuoto K; Bascom Palmer Eye Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida.
  • Leong J; The University of Sydney, Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, Sydney, New South Wales, Australia; Save Sight Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Rousselot Ascarza A; Consultorios Oftalmológicos Benisek-Ascarza, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
  • Woreta FA; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Miller KE; Uniformed Services University of the Health Sciences, Bethesda, Maryland; Department of Ophthalmology, Navy Medical Center Portsmouth, Portsmouth, Virginia.
  • Caldwell MC; Department of Ophthalmology, San Antonio Uniformed Services Health Education Consortium, San Antonio, Texas.
  • Gensheimer WG; Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; White River Junction Veterans Administration Medical Center, White River Junction, Vermont.
  • Williamson T; Department of Ophthalmology, St. Thomas Hospital, London, United Kingdom.
  • Dhawahir-Scala F; Manchester Royal Eye Hospital, Manchester, United Kingdom.
  • Shah P; Birmingham Institute for Glaucoma Research, Birmingham, United Kingdom; Department of Ophthalmology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • Coombes A; Department of Ophthalmology, The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Sundar G; Department of Ophthalmology, National University Hospital, Singapore, Republic of Singapore.
  • Mazzoli RA; Uniformed Services University of the Health Sciences, Bethesda, Maryland.
  • Woodcock M; Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom.
  • Watson SL; Save Sight Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Kuhn F; Helen Keller Foundation for Research and Education, Birmingham, Alabama.
  • Halliday S; Research & Innovation, BRAVO VICTOR, London, United Kingdom.
  • Gomes RSM; Research & Innovation, BRAVO VICTOR, London, United Kingdom; Northern Hub for Veterans and Military Families Research, Northumbria University, Newcastle, United Kingdom.
  • Agrawal R; National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Republic of Singapore; Singapore Eye Research Institute, Singapore, Republic of Singapore; Lee Kong Chian School of Medicine, Singapore, Republic of Singapore; Duke NUS Medical School, Singapore, Republic of Singapore.
  • Blanch RJ; Department of Ophthalmology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; Neuroscience & Ophthalmology, Institute of Inflammation & Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Ophthal
Ophthalmology ; 131(5): 557-567, 2024 May.
Article en En | MEDLINE | ID: mdl-38086434
ABSTRACT
TOPIC Sympathetic ophthalmia (SO) is a sight-threatening granulomatous panuveitis caused by a sensitizing event. Primary enucleation or primary evisceration, versus primary repair, as a risk management strategy after open-globe injury (OGI) remains controversial. CLINICAL RELEVANCE This systematic review was conducted to report the incidence of SO after primary repair compared with that of after primary enucleation or primary evisceration. This enabled the reporting of an estimated number needed to treat.

METHODS:

Five journal databases were searched. This review was registered with International Prospective Register of Systematic Reviews (identifier, CRD42021262616). Searches were carried out on June 29, 2021, and were updated on December 10, 2022. Prospective or retrospective studies that reported outcomes (including SO or lack of SO) in a patient population who underwent either primary repair and primary enucleation or primary evisceration were included. A systematic review and meta-analysis were carried out in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Random effects modelling was used to estimate pooled SO rates and absolute risk reduction (ARR).

RESULTS:

Eight studies reporting SO as an outcome were included in total. The included studies contained 7500 patients and 7635 OGIs. In total, 7620 OGIs met the criteria for inclusion in this analysis; SO developed in 21 patients with OGI. When all included studies were pooled, the estimated SO rate was 0.12% (95% confidence interval [CI], 0.00%-0.25%) after OGI. Of 779 patients who underwent primary enucleation or primary evisceration, no SO cases were reported, resulting in a pooled SO estimate of 0.05% (95% CI, 0.00%-0.21%). For primary repair, the pooled estimate of SO rate was 0.15% (95% CI, 0.00%-0.33%). The ARR using a random effects model was -0.0010 (in favour of eye removal; 95% CI, -0.0031 [in favor of eye removal] to 0.0011 [in favor of primary repair]). Grading of Recommendations, Assessment, Development, and Evaluations analysis highlighted a low certainty of evidence because the included studies were observational, and a risk of bias resulted from missing data.

DISCUSSION:

Based on the available data, no evidence exists that primary enucleation or primary evisceration reduce the risk of secondary SO. FINANCIAL DISCLOSURE(S) Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: Ophthalmology Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: Ophthalmology Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido